QIAGEN (QGEN) Stock: Buy, Sell, or Hold?
QGEN - QIAGEN N.V.
$42.04
-1.72 (-3.93%)
▼
5d:
-5.66%
30d:
-3.11%
90d:
+4.84%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When QGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: QGEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: QGEN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$55.15
Based on 5.7% avg growth
INTRINSIC VALUE TODAY
$34.24
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: QGEN is currently trading at $42.04, which is considered oversold relative to its 30-day fair value range of $42.49 to $44.26. The stock's valuation (Forward PE: 16.1) is in line with its historical norms (16.0). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, QGEN is showing support break momentum. The price is currently testing key support at $41.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $46.27 (+10.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QGEN is showing support break momentum. The price is currently testing key support at $41.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $46.27 (+10.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$42.49 -
$44.26
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading below Wall St target ($46.27)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$42.49 -
$44.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$41.94
Resistance Level
$45.53
Current Trend
Support Break
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.09
Wall Street Target
$46.27
(+10.1%)
Revenue Growth (YoY)
0.3%
Earnings Growth (YoY)
7.9%
Profit Margin
19.5%
Valuation Premium vs History
+0.2% premium
PE vs Historical
16.1 vs 16.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$42.12
(+0%)
2-Year Target
$42.21
(+0%)
3-Year Target
$42.29
(+1%)
3-Yr Target (if PE normalizes)
(PE: 16→16)
PE COMPRESSION
$42.06
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 7.4%)
$66.00
(+57%)
Base:
(SPY PE: 16.1, Growth: 7.4%)
$52.04
(+24%)
Bear:
(PE: 13.7, Growth: 7.4%)
$44.24
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 22.56 | Current EPS (TTM): $1.94
Bull Case
$64.84
(+54%)
Analyst growth 34.7%, PE expands to 24.8
Base Case
$58.95
(+40%)
Market implied 34.7%, PE stable at 22.6
Bear Case
$29.76
(-29%)
Severe decline -20.0%, PE contracts to 19.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 4:54 AM ET
Data refreshes hourly during market hours. Next update: 5:54 AM
Data refreshes hourly during market hours. Next update: 5:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 43 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$231 | 48 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$196 | 46 HOLD |
|
LH
Laboratory Corporation o… |
STRONG BUY
20 analysts |
$345 | 65 BUY |
